Literature DB >> 22348189

Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs.

De Socio Giuseppe Vittorio1, D'Avolio Antonio, Sgrelli Alessio, Baietto Lorena, Lisa Malincarne, Di Perri Giovanni, Baldelli Franco.   

Abstract

We report pharmacokinetic data on two gastrectomized, patients affected by tuberculosis. Drugs plasmatic concentrations were measured after seven days of oral therapy by a validated high performance liquid chromatography-mass spectrometry (HPLC-MS) method and the area under the concentration-time-curve (AUC) over 24 hours (AUC(0-24)) was calculated. A sub-therapeutic level of isoniazid was found in a patient with total gastrectomy with a C(max) of 0,395 mg\L and AUC(0-24) level of 4.75 hr*mg/L. The level of the other antitubercular drugs was adequate. These findings support the need to monitor anti tubercular drug levels to facilitate early detection of therapeutic failure, above all in patients treated with isoniazid and with potential problems on oral drugs absorption.

Entities:  

Year:  2012        PMID: 22348189      PMCID: PMC3279322          DOI: 10.4084/MJHID.2012.007

Source DB:  PubMed          Journal:  Mediterr J Hematol Infect Dis        ISSN: 2035-3006            Impact factor:   2.576


  9 in total

1.  Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

Authors:  Marc Weiner; William Burman; Andrew Vernon; Debra Benator; Charles A Peloquin; Awal Khan; Stephen Weis; Barbara King; Nina Shah; Thomas Hodge
Journal:  Am J Respir Crit Care Med       Date:  2003-01-16       Impact factor: 21.405

2.  Pulmonary tuberculosis after gastric resection.

Authors:  Z Steiger; W O Nickel; G J Shannon; E G Nedwicki; R F Higgins
Journal:  Am J Surg       Date:  1976-06       Impact factor: 2.565

3.  Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.

Authors:  M E Kimerling; P Phillips; P Patterson; M Hall; C A Robinson; N E Dunlap
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

4.  Tuberculosis and gastrectomy.

Authors:  D E Snider
Journal:  Chest       Date:  1985-04       Impact factor: 9.410

5.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  A simulation study to evaluate limited sampling strategies to estimate area under the curve of drug concentration versus time following repetitive oral dosing: limited sampling model versus naive trapezoidal method.

Authors:  Yuichiro Kayano; Isao Horiuchi; Yun-i Mori; Kazuya Ishida; Tomohisa Saito; Masato Taguchi; Yukiya Hashimoto
Journal:  Biol Pharm Bull       Date:  2009-08       Impact factor: 2.233

7.  Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.

Authors:  S-W Um; S W Lee; S Y Kwon; H I Yoon; K U Park; J Song; C-T Lee; J-H Lee
Journal:  Int J Tuberc Lung Dis       Date:  2007-09       Impact factor: 2.373

8.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

9.  The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Authors:  P R Donald; D P Parkin; H I Seifart; H S Schaaf; P D van Helden; C J Werely; F A Sirgel; A Venter; J S Maritz
Journal:  Eur J Clin Pharmacol       Date:  2007-05-16       Impact factor: 3.064

  9 in total
  1 in total

Review 1.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.